tislelizumab + carboplatin + cisplatin + etoposide

This agent is a combination of four drugs: **tislelizumab**, **carboplatin**, **cisplatin**, and **etoposide**. The combination is under investigation or in clinical use for oncology indications, particularly various advanced cancers. - **Tislelizumab** is a humanized monoclonal IgG4 antibody targeting programmed death receptor-1 (**PD-1**) on T-cells. It inhibits the PD-1/PD-L1 pathway, thus enhancing the immune system's ability to recognize and attack tumor cells[1][3][5][7]. It has been engineered to minimize Fcγ receptor binding, reducing immune cell depletion and possibly improving efficacy. - **Carboplatin** and **cisplatin** are platinum-based chemotherapeutic agents that cause DNA crosslinking and apoptosis in rapidly dividing cells, with distinct toxicity profiles[2][4]. They are widely used in combination regimens for solid tumors. - **Etoposide** is a topoisomerase II inhibitor, leading to DNA strand breaks and inhibition of DNA synthesis, with broad activity against a variety of cancers[2][6]. The combination of platinum compounds (cisplatin/carboplatin) and etoposide forms the backbone of chemotherapy in small cell lung cancer (SCLC) and other malignancies, with evidence supporting the use of both agents in the same regimen for advanced-stage disease[2][4]. Addition of immune checkpoint inhibitors like tislelizumab is being explored to enhance anti-tumor efficacy[5][7].

Brand names

Tevimbra (for tislelizumab)

Other names

carboplatin + cisplatin + etoposide + tislelizumab